What is tirzepatide used for in research?

Research and clinical use cover type 2 diabetes, obesity, and increasingly cardiovascular outcomes, sleep apnea, and metabolic liver disease. It's currently the most effective pharmacological weight management agent approved. For research purposes only.

How does tirzepatide compare to semaglutide?

Both are weekly-dose incretin agonists. Semaglutide activates only GLP-1; tirzepatide activates both GLP-1 and GIP. Head-to-head trials (SURPASS-2, SURMOUNT-5) show tirzepatide produces larger weight reduction, though semaglutide has a more mature cardiovascular outcomes dataset. For research purposes only.

What's the typical titration schedule for tirzepatide?

Research and clinical protocols titrate gradually, starting at 2.5 mg weekly and increasing every 4 weeks. Gastrointestinal side effects are dose-related and the gradual titration is designed to minimize them. For research purposes only.

Tirzepatide - NOVIS

Research Parameters

Typical Dose Range: Clinical: 2.5 mg weekly titrating up to 15 mg weekly (Zepbound for obesity). 2.5 mg weekly titrating up to 15 mg weekly (Mounjaro for diabetes).
Half-Life: ~5 days (~120 hours)
Administration Route: Subcutaneous

Dosing information is for research purposes only and has not been evaluated by the FDA.

Tirzepatide is what happened when researchers asked: what if we took semaglutide's mechanism and added a second one on top? The answer produced the strongest weight management data ever recorded in pharmacology. The SURMOUNT-1 trial showed an average of 21% body weight reduction at the highest dose over 72 weeks, meaningfully larger than semaglutide in the head-to-head SURMOUNT-5 trial. Approved as Mounjaro for type 2 diabetes in 2022, and as Zepbound for obesity in 2023.

For anyone in the body composition research space paying attention, the tradeoffs of tirzepatide versus semaglutide matter. Larger weight loss, but shorter cardiovascular outcomes dataset (semaglutide's SELECT trial is the benchmark there, and tirzepatide's equivalent is still running). Same concerns apply around lean mass loss when the weight loss is rapid and protein intake and training stimulus aren't deliberately maintained.

For research purposes only.

Mechanism of Action

Tirzepatide is a dual GLP-1 / GIP receptor agonist. It activates both of the primary incretin receptor pathways, where semaglutide activates only GLP-1. That dual activation is the source of the larger effect size. A ~5-day half-life enables weekly dosing.

Citations

Frequently Asked Questions

What is tirzepatide used for in research?: Research and clinical use cover type 2 diabetes, obesity, and increasingly cardiovascular outcomes, sleep apnea, and metabolic liver disease. It's currently the most effective pharmacological weight management agent approved. For research purposes only.
How does tirzepatide compare to semaglutide?: Both are weekly-dose incretin agonists. Semaglutide activates only GLP-1; tirzepatide activates both GLP-1 and GIP. Head-to-head trials (SURPASS-2, SURMOUNT-5) show tirzepatide produces larger weight reduction, though semaglutide has a more mature cardiovascular outcomes dataset. For research purposes only.
What's the typical titration schedule for tirzepatide?: Research and clinical protocols titrate gradually, starting at 2.5 mg weekly and increasing every 4 weeks. Gastrointestinal side effects are dose-related and the gradual titration is designed to minimize them. For research purposes only.

Related Peptides

BPC-157 + TB-500 Stack BPC-157 + TB-500 Recovery Stack Protocol MOTS-c MOTS-c (Mitochondrial ORF of the 12S rRNA-c) NAD+ NAD+ (Nicotinamide Adenine Dinucleotide)